The world of pharmaceutical antitrust litigation is on the brink of notable change, with focus swiftly shifting towards biologics and biosimilars. Legal professionals must adapt to this evolving landscape by modifying their strategies to accommodate for these complex and innovate drugs, which exhibit distinctive market dynamics. Specialists are highlighting ways that biosimilar markets differ from traditional small-molecule drug markets, and as a result, new tactics for handling pharmaceutical antitrust cases are imperative.
Furthermore, cases involving the delayed market entry of generic pharmaceuticals have traditionally centred on small-molecule generic drugs. However, according to Aaron Marks of Cohen Milstein, the industry should brace itself for a future of litigation where biologics and biosimilars take the spotlight.
Marks underscores the necessity of considering fresh response measures in cases that encompass these emerging sectors. There is no question that pharmaceutical antitrust litigators must be well-versed in these unwavering market dynamics as they prepare for an influx of biosimilar-delay cases.
This Law360 article provides greater insight into these challenges, including expert analysis and valuable tips for navigating this uncharted territory.